menu
Showcases Stock ranks

Ra Pharmaceuticals Inc. (RARX) (RARX)
46.9 -0.06 (-0.13%) 03-27 16:00
Open: 47.01 Pre. Close: 47.56
High: 47.355 Low: 46.78
Volume: 1,228,860 Market Cap: 2220M
Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.
Share on Facebook   Tweet this page
Price Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 47.37 - 47.689 47.689 - 47.953
Low: 46.163 - 46.476 46.476 - 46.736
Close: 46.442 - 46.95 46.95 - 47.37
Stock Technical Analysis
Overall:     
Target: Six months: 55.80
One year: 65.17
Support: Support1: 43.15
Support2: 40.30
Resistance: Resistance1: 47.77
Resistance2: 55.80
Pivot: 45.60
Moving Averages: MA(5): 46.55
MA(20): 45.91
MA(100): 46.63
MA(250): 35.75
MACD: MACD(12,26): -0.02
Signal(12,26,9): -0.27
%K %D: %K(14,3): 91.57
%D(3): 88.56
RSI: RSI(14): 53.85
52-Week: High: 47.77
Low: 19.64
Change(%): 125.6
Average Vol(K): 3-Month: 101130
10-Days: 179110
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

RARX has closed below upper band by 29.9%. Bollinger Bands are 407.1% wider than normal. The large width of the bands suggest high volatility as compared to RARX's normal range. The bands have been in this wide range for 7 bars. This is a sign that the current trend might continue.
Stock chart
Stock News
2020-02-27
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced financial results for the fourth quarter and year ended December 31, 2019, and provided an update on recent corporate and clinical developments. “2019 was a transformational year for Ra Pharma in our efforts to discover, develop, and expand access to important therapies for patients with rare diseases, including the strengthening of our balance sheet with a $150 million financing and the advancement of key

2020-02-18
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA Neurology. The JAMA Neurology publication can be accessed here. “This publication in JAMA Neurology recognizes the impact and significance of the findings from our Phase 2 clinical trial demonstrating zilucoplan’s potential in gMG, a chronic and debilitating neu

Financial Analysis
Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 47.15
Shares Float (M) 35.91
% Held by Insiders 4.03
% Held by Institutions 106.17
Shares Short (K) 5650
Shares Short Prior Month (K) 9170
Stock Financials
EPS -2.320
Book Value (p.s.) 5.550
PEG Ratio
Profit Margin
Operating Margin -3565.97
Return on Assets (ttm) -26.6
Return on Equity (ttm) -43.8
Qtrly Rev. Growth -100.0
Gross Profit (p.s.) 0.064
Sales Per Share 0.064
EBITDA (p.s.) -2.235
Qtrly Earnings Growth
Operating Cash Flow (M) -87.36
Levered Free Cash Flow (M) -52.39
Stock Valuation
P/E -20.22
P/E Growth Ratio
P/BV 8.45
P/S
P/CF -25.31
Dividend Yield
Dividends & Splits
Dividend
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator